EGFR and non-small cell lung carcinoma: In-frame deletions in exon 19 (delE746_A750 or del19) and L858R insertion in exon 21, referred to as “common mutations”, are the oncogenic drivers for the development of more than 90% of the reported NSCLC cases found positive for a mutation of EGFR, reported with an increased incidence in Asian non-smoker females with a late-stage adenocarcinoma malignancy [65,66,67].